OTCMKTS:MYMXMymetics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mymetics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.05 0.00 (0.00 %) (As of 07/13/2020 04:00 PM ET) Add Compare Share Today's Range$0.05Now: $0.05▼$0.0550-Day Range$0.04MA: $0.05▼$0.0652-Week Range$0.02Now: $0.05▼$0.07Volume3,100 shsAverage Volume137,727 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABeta-0.21 ProfileAdvanced ChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Mymetics Corporation, a vaccine company, focuses on developing vaccines for infectious diseases primarily in Switzerland. The company's product pipeline includes vaccine candidates, such as HIV-1/AIDS, intra nasal influenza, malaria, chikungunya, herpes simplex virus, and the respiratory syncitial virus (RSV) vaccine. It has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative; the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; RSV Corporation for developing the RSV vaccine; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Mymetics. Previous Next 2.3 Community Rank Outperform VotesMymetics has received 63 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMymetics has received 72 “underperform” votes. (Add your “underperform” vote.)Community SentimentMymetics has received 53.33% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mymetics and other stocks. Vote “Outperform” if you believe MYMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MYMX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMymetics does not currently pay a dividend.Dividend GrowthMymetics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mymetics insiders have not sold or bought any company stock.Percentage Held by Insiders54.18% of the stock of Mymetics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.66 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MYMX Previous Symbol CUSIPN/A CIK927761 Webwww.mymetics.com Phone41-21-653-4535Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$730,000.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.18) per share Price / Book-0.28Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-4,690,000.00 Net Margins-613.29% Return on EquityN/A Return on Assets-54.56%Miscellaneous Employees8 Outstanding SharesN/AMarket CapN/A Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable OTC:MYMX Rates by TradingView Receive MYMX News and Ratings via Email Sign-up to receive the latest news and ratings for MYMX and its competitors with MarketBeat's FREE daily newsletter. Mymetics (OTCMKTS:MYMX) Frequently Asked Questions How has Mymetics' stock been impacted by COVID-19 (Coronavirus)? Mymetics' stock was trading at $0.0379 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MYMX shares have increased by 31.9% and is now trading at $0.05. View which stocks have been most impacted by Coronavirus. When is Mymetics' next earnings date? Mymetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Mymetics. Has Mymetics been receiving favorable news coverage? Headlines about MYMX stock have been trending very negative on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mymetics earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Mymetics. Who are some of Mymetics' key competitors? Some companies that are related to Mymetics include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Seattle Genetics (SGEN), Moderna (MRNA), NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Neurocrine Biosciences (NBIX), argenx (ARGX), BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Mymetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mymetics investors own include Genocea Biosciences (GNCA), BlackBerry (BB), Boeing (BA), Activision Blizzard (ATVI), Asure Software (ASUR), Array Biopharma (ARRY), Arlo Technologies (ARLO), Appian (APPN), Aphria (APHA) and Apache (APA). Who are Mymetics' key executives? Mymetics' management team includes the following people: Mr. Ronald Kempers, CEO, Pres & CFO (Age 51)Dr. Sylvain Fleury, Chief Scientific Officer (Age 57)Mr. Anthony Jessop, Sr. VP (Age 78)Dr. Antonius Johannes Stegmann, Head of R&D and Chief Scientific Officer of Mymetics BVMr. Mario Amacker Ph.D., Head of Quality & Manufacturing What is Mymetics' stock symbol? Mymetics trades on the OTCMKTS under the ticker symbol "MYMX." How do I buy shares of Mymetics? Shares of MYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Mymetics' stock price today? One share of MYMX stock can currently be purchased for approximately $0.05. What is Mymetics' official website? The official website for Mymetics is www.mymetics.com. How can I contact Mymetics? Mymetics' mailing address is Route de la Corniche 4, Epalinges V8, CH-1066. The company can be reached via phone at 41-21-653-4535 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
